CrushSCI.com
85.9Average days
64Median days
34Fastest days
176Longest days
3742025 publications

Paper Review Records

All Paper Review Records

14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

176 days

FABP4+ macrophages promote glycolysis in lung cancer progression through the TNF-α–MYC pathway

Authors
Lingwei Liu; Weibin Shu; Chuanxi Wang; Qiang Wen; Hongchang Shen; Qiang Li; Keying CheShow moreShow less
Affiliations
1. Department of Nuclear Medicine, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, China; 2. Tumor Research and Therapy Center, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, ChinaShow moreShow less
Official full-text evidence DOI Publisher page
149 days

Dendritic cells enhance tebentafusp-mediated T cell effector responses

Authors
Manuel Wiesinger; Anne Petzold; Markus Luber; Philipp Hilgendorf; Andreas Wild; Markus Vincent Heppt; Beatrice Schuler‐Thurner; Kilian Schober; Carola Berking; Elias A. T. KochShow moreShow less
Affiliations
1. Friedrich-Alexander-Universität Erlangen-Nürnberg; 2. Universitätsklinikum Erlangen; 3. Comprehensive Cancer Center ErlangenShow moreShow less
Source PDF DOI Publisher page
34 days

Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis

Authors
K. E. Blethen; C. P. Wolford; G. L. Pecar; T. A. Arsiwala; E. Adjeroh; L. P. Dykstra; B. N. Kielkowski; P. R. LockmanShow moreShow less
Affiliations
1. Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, USA; 2. Rockefeller Neuroscience Institute, West Virginia University, Morgantown, USAShow moreShow less
Source PDF DOI Publisher page
134 days

Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma

Authors
Feihua Chen; Mouchun Gong; Dengcheng Weng; Zhaoqing Jin; Guofeng Han; Ziqiang Yang; Junjun Han; Jianjiang WangShow moreShow less
Affiliations
1. Department of General Surgery, Hangzhou Medical College Affiliated Lin’an People’s Hospital, Hangzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
34 days

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

Authors
Joanna Baginska; Allison Nau; Ilana Gomez Diaz; Anita Giobbie-Hurder; Jason Weirather; Juliana Vergara; Charlotte Abrecht; Margaret Hallisey; Jenna Dennis; Mariano Severgnini; Julia Huezo; Isabella Marciello; Osama Rahma; Michael Manos; Andrew S. Brohl; Philippe L. Bedard; Daniel J. Renouf; Elad Sharon; Howard Streicher; Patrick A. Ott; Elizabeth I. Buchbinder; F. Stephen HodiShow moreShow less
Affiliations
1. Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, USA; 2. Department of Data Science, Dana-Farber Cancer Institute, Boston, USA; 3. Sarcoma Department and Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA; 4. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; 5. Cancer and Department of Medicine, University of British Columbia, Vancouver, Canada; 6. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USAShow moreShow less
Source PDF DOI Publisher page
35 days

Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice

Authors
Akashdip Singh; Eline T. A. M. Mommers-Elshof; Saskia V. Vijver; J. H. Marco Jansen; Susanne Gonder; Robert Jan Lebbink; Dominique Bihan; Richard W. Farndale; Louis Boon; Solomon Langermann; Jeanette H. W. Leusen; Dallas Flies; Linde Meyaard; M. Ines Pascoal RamosShow moreShow less
Affiliations
1. Centre for Translational Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands; 2. Oncode Institute, Utrecht, The Netherlands; 3. Department of Biochemistry, University of Cambridge, Cambridge, UK; 4. JJP Biologics, Warsaw, Poland; 5. Nextcure, Beltsville, USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does CANCER IMMUNOLOGY IMMUNOTHERAPY take to review a manuscript?

As of 2026-11-19, CrushSCI has 14 complete review records for CANCER IMMUNOLOGY IMMUNOTHERAPY. The fastest paper went from submission to acceptance in 34 days (Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis, received 2023-10-03, accepted 2023-11-06); the slowest took 176 days. The average is 85.9 days and the median is 64 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.